Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.

Phillips T, Millett MM, Zhang X, Jansson M, Cleveland R, Simmons P, Cherryholmes G, Carnahan J, William J, Spaulding B, Satnick IR, Inzunza HD, Taylor C, Cogswell J, Novotny J, Oroudjev E, Winther H.

Appl Immunohistochem Mol Morphol. 2018 Jan;26(1):6-12. doi: 10.1097/PAI.0000000000000605.

2.

Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.

Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.

Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.

PMID:
28766224
3.

ORAL01.02: Biopsies in Initial Diagnosis of Non-Small Cell Lung Cancer in US Community Oncology Practices: Implications for First-Line Immunotherapy: Topic: Medical Oncology.

Hussein M, Richards DA, Ulrich B, Korytowsky B, Pandya D, Cogswell J, Batenchuk C, Burns V.

J Thorac Oncol. 2016 Nov;11(11S):S249-S250. doi: 10.1016/j.jtho.2016.09.007. Epub 2016 Oct 28. No abstract available.

4.
5.

An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.

Cogswell J, Inzunza HD, Wu Q, Feder JN, Mintier G, Novotny J, Cardona DM.

Mol Diagn Ther. 2017 Feb;21(1):85-93. doi: 10.1007/s40291-016-0237-9.

6.

Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.

Novotny JF Jr, Cogswell J, Inzunza H, Harbison C, Horak C, Averbuch S.

Ann Oncol. 2016 Oct;27(10):1966-9. doi: 10.1093/annonc/mdw288. Epub 2016 Aug 8. No abstract available.

7.

Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.

Chiba A, Hoskin TL, Hallberg EJ, Cogswell JA, Heins CN, Couch FJ, Boughey JC.

Ann Surg Oncol. 2016 Oct;23(10):3232-8. doi: 10.1245/s10434-016-5328-7. Epub 2016 Jun 23.

8.

Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.

Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr, Taylor C, Zhang X.

Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-9. doi: 10.1097/PAI.0000000000000256.

9.

IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.

Huang F, Chang H, Greer A, Hillerman S, Reeves KA, Hurlburt W, Cogswell J, Patel D, Qi Z, Fairchild C, Ryseck RP, Wong TW, Finckenstein FG, Jackson J, Carboni JM.

Mol Cancer Ther. 2015 Feb;14(2):620-30. doi: 10.1158/1535-7163.MCT-14-0794-T. Epub 2014 Dec 19.

10.

Prevalence of restless legs syndrome and sleep quality in carriers of the fragile X premutation.

Summers SM, Cogswell J, Goodrich JE, Mu Y, Nguyen DV, Brass SD, Hagerman RJ.

Clin Genet. 2014 Aug;86(2):181-4.

11.

Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.

Seritan AL, Nguyen DV, Mu Y, Tassone F, Bourgeois JA, Schneider A, Cogswell JB, Cook KR, Leehey MA, Grigsby J, Olichney JM, Adams PE, Legg W, Zhang L, Hagerman PJ, Hagerman RJ.

J Clin Psychiatry. 2014 Mar;75(3):264-71. doi: 10.4088/JCP.13m08546.

12.

COGNITIVE DYSFUNCTION IN FMR1 PREMUTATION CARRIERS.

Seritan A, Cogswell J, Grigsby J.

Curr Psychiatry Rev. 2013 Feb;9(1):78-84.

13.

Mutations in the hedgehog pathway genes SMO and PTCH1 in human gastric tumors.

Wang XD, Inzunza H, Chang H, Qi Z, Hu B, Malone D, Cogswell J.

PLoS One. 2013;8(1):e54415. doi: 10.1371/journal.pone.0054415. Epub 2013 Jan 18.

14.

A fluidic diode, valves, and a sequential-loading circuit fabricated on layered paper.

Chen H, Cogswell J, Anagnostopoulos C, Faghri M.

Lab Chip. 2012 Aug 21;12(16):2909-13. doi: 10.1039/c2lc20970e. Epub 2012 Jun 14.

PMID:
22699228
15.

An immune-active tumor microenvironment favors clinical response to ipilimumab.

Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, Jackson JR, Shahabi V.

Cancer Immunol Immunother. 2012 Jul;61(7):1019-31. doi: 10.1007/s00262-011-1172-6. Epub 2011 Dec 7.

PMID:
22146893
16.

Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.

Ortigas MC, Bourgeois JA, Schneider A, Olichney J, Nguyen DV, Cogswell JB, Hall DA, Hagerman RJ.

J Clin Psychopharmacol. 2010 Oct;30(5):642-4. doi: 10.1097/JCP.0b013e3181f1d10a. No abstract available.

17.

Large polyoxotitanate clusters: well-defined models for pure-phase TiO2 structures and surfaces.

Benedict JB, Freindorf R, Trzop E, Cogswell J, Coppens P.

J Am Chem Soc. 2010 Oct 6;132(39):13669-71. doi: 10.1021/ja106436y.

PMID:
20836494
18.

Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers.

Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ.

J Clin Psychiatry. 2011 Feb;72(2):175-82. doi: 10.4088/JCP.09m05407blu. Epub 2010 Aug 24.

19.

Functional status of men with the fragile X premutation, with and without the tremor/ataxia syndrome (FXTAS).

Brega AG, Reynolds A, Bennett RE, Leehey MA, Bounds LS, Cogswell JB, Hagerman RJ, Hagerman PJ, Grigsby J.

Int J Geriatr Psychiatry. 2009 Oct;24(10):1101-9. doi: 10.1002/gps.2231.

20.

Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with non-small-cell lung cancer.

George S, Kasimis BS, Cogswell J, Schwarzenberger P, Shapiro GI, Fidias P, Bukowski RM.

Clin Lung Cancer. 2008 May;9(3):160-5. doi: 10.3816/CLC.2008.n.024.

PMID:
18621626
21.

The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome.

Brega AG, Goodrich G, Bennett RE, Hessl D, Engle K, Leehey MA, Bounds LS, Paulich MJ, Hagerman RJ, Hagerman PJ, Cogswell JB, Tassone F, Reynolds A, Kooken R, Kenny M, Grigsby J.

J Clin Exp Neuropsychol. 2008 Nov;30(8):853-69. doi: 10.1080/13803390701819044. Epub 2008 Feb 15.

22.

Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways.

Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA.

J Alzheimers Dis. 2008 May;14(1):27-41.

PMID:
18525125
23.

Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.

Grigsby J, Brega AG, Engle K, Leehey MA, Hagerman RJ, Tassone F, Hessl D, Hagerman PJ, Cogswell JB, Bennett RE, Cook K, Hall DA, Bounds LS, Paulich MJ, Reynolds A.

Neuropsychology. 2008 Jan;22(1):48-60. doi: 10.1037/0894-4105.22.1.48.

PMID:
18211155
24.

FMR1 CGG repeat length predicts motor dysfunction in premutation carriers.

Leehey MA, Berry-Kravis E, Goetz CG, Zhang L, Hall DA, Li L, Rice CD, Lara R, Cogswell J, Reynolds A, Gane L, Jacquemont S, Tassone F, Grigsby J, Hagerman RJ, Hagerman PJ.

Neurology. 2008 Apr 15;70(16 Pt 2):1397-402. Epub 2007 Dec 5.

25.

Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome.

Bourgeois JA, Cogswell JB, Hessl D, Zhang L, Ono MY, Tassone F, Farzin F, Brunberg JA, Grigsby J, Hagerman RJ.

Gen Hosp Psychiatry. 2007 Jul-Aug;29(4):349-56.

26.

Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome.

Grigsby J, Brega AG, Leehey MA, Goodrich GK, Jacquemont S, Loesch DZ, Cogswell JB, Epstein J, Wilson R, Jardini T, Gould E, Bennett RE, Hessl D, Cohen S, Cook K, Tassone F, Hagerman PJ, Hagerman RJ.

Mov Disord. 2007 Apr 15;22(5):645-50.

PMID:
17266074
27.

Neuropathic features in fragile X premutation carriers.

Berry-Kravis E, Goetz CG, Leehey MA, Hagerman RJ, Zhang L, Li L, Nguyen D, Hall DA, Tartaglia N, Cogswell J, Tassone F, Hagerman PJ.

Am J Med Genet A. 2007 Jan 1;143A(1):19-26.

PMID:
17152065
28.

Progression of tremor and ataxia in male carriers of the FMR1 premutation.

Leehey MA, Berry-Kravis E, Min SJ, Hall DA, Rice CD, Zhang L, Grigsby J, Greco CM, Reynolds A, Lara R, Cogswell J, Jacquemont S, Hessl DR, Tassone F, Hagerman R, Hagerman PJ.

Mov Disord. 2007 Jan 15;22(2):203-6.

PMID:
17133502
29.

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson SA, Hagerman R.

J Child Adolesc Psychopharmacol. 2006 Oct;16(5):525-40.

PMID:
17069542
30.

Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome.

Cohen S, Masyn K, Adams J, Hessl D, Rivera S, Tassone F, Brunberg J, DeCarli C, Zhang L, Cogswell J, Loesch D, Leehey M, Grigsby J, Hagerman PJ, Hagerman R.

Neurology. 2006 Oct 24;67(8):1426-31.

PMID:
17060569
31.

Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS).

Grigsby J, Brega AG, Jacquemont S, Loesch DZ, Leehey MA, Goodrich GK, Hagerman RJ, Epstein J, Wilson R, Cogswell JB, Jardini T, Tassone F, Hagerman PJ.

J Neurol Sci. 2006 Oct 25;248(1-2):227-33. Epub 2006 Jun 15.

PMID:
16780889
32.

Tightening seat belts.

Cogswell J, Hipp L.

Miss RN. 2006 Spring;68(1):5. No abstract available.

PMID:
16625806
33.

Knowledge and attitudes toward end-of-life care in veterans with symptomatic metastatic cancer.

Hwang SS, Chang VT, Cogswell J, Srinivas S, Kasimis B.

Palliat Support Care. 2003 Sep;1(3):221-30.

PMID:
16594422
34.

Caregiver unmet needs, burden, and satisfaction in symptomatic advanced cancer patients at a Veterans Affairs (VA) medical center.

Hwang SS, Chang VT, Alejandro Y, Osenenko P, Davis C, Cogswell J, Srinivas S, Kasimis B.

Palliat Support Care. 2003 Dec;1(4):319-29.

PMID:
16594221
35.

Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia.

Bacalman S, Farzin F, Bourgeois JA, Cogswell J, Goodlin-Jones BL, Gane LW, Grigsby J, Leehey MA, Tassone F, Hagerman RJ.

J Clin Psychiatry. 2006 Jan;67(1):87-94.

PMID:
16426093
36.

Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS).

Hall DA, Berry-Kravis E, Jacquemont S, Rice CD, Cogswell J, Zhang L, Hagerman RJ, Hagerman PJ, Leehey MA.

Neurology. 2005 Jul 26;65(2):299-301. Erratum in: Neurology. 2005 Sep 13;65(5):784.

PMID:
16043804
37.

Quantitative analysis of orphan G protein-coupled receptor mRNAs by TaqMan Real-Time PCR: G2A and GPR4 lysophospholipid receptor expression in leukocytes and in a rat myocardial infarction-heart failure model.

Douglas SA, Ao Z, Johns DG, Maniscalco K, Willette RN, Sarov-Blat L, Cogswell JP, Seepersaud S, Murdock P, Steplewski KM, Patel L.

Methods Mol Biol. 2005;306:27-49. No abstract available.

PMID:
15867463
38.

Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.

Nagaria NC, Cogswell J, Choe JK, Kasimis B.

J Clin Oncol. 2005 Apr 1;23(10):2423-4. No abstract available.

PMID:
15800334
39.

Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center.

Hwang SS, Chang VT, Alejandro Y, Mulaparthi S, Cogswell J, Srinivas S, Kasimis B.

Cancer Invest. 2004;22(6):849-57.

PMID:
15641482
40.
41.

Study of unmet needs in symptomatic veterans with advanced cancer: incidence, independent predictors and unmet needs outcome model.

Hwang SS, Chang VT, Cogswell J, Alejandro Y, Osenenko P, Morales E, Srinivas S, Kasimis B.

J Pain Symptom Manage. 2004 Nov;28(5):421-32.

PMID:
15504619
42.

Polo-like kinases and the microtubule organization center: targets for cancer therapies.

Dai W, Cogswell JP.

Prog Cell Cycle Res. 2003;5:327-34. Review.

PMID:
14593727
43.

Longitudinal quality of life in advanced cancer patients: pilot study results from a VA medical cancer center.

Hwang SS, Chang VT, Fairclough DL, Cogswell J, Kasimis B.

J Pain Symptom Manage. 2003 Mar;25(3):225-35.

PMID:
12614957
44.

Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2.

Xie S, Wu H, Wang Q, Kunicki J, Thomas RO, Hollingsworth RE, Cogswell J, Dai W.

Cell Cycle. 2002 Nov-Dec;1(6):424-9.

PMID:
12548019
45.

Clinical relevance of fatigue levels in cancer patients at a Veterans Administration Medical Center.

Hwang SS, Chang VT, Cogswell J, Kasimis BS.

Cancer. 2002 May 1;94(9):2481-9.

46.

A birth cohort study of subjects at risk of atopy: twenty-two-year follow-up of wheeze and atopic status.

Rhodes HL, Thomas P, Sporik R, Holgate ST, Cogswell JJ.

Am J Respir Crit Care Med. 2002 Jan 15;165(2):176-80.

PMID:
11790650
47.

Early life risk factors for adult asthma: a birth cohort study of subjects at risk.

Rhodes HL, Sporik R, Thomas P, Holgate ST, Cogswell JJ.

J Allergy Clin Immunol. 2001 Nov;108(5):720-5.

PMID:
11692095
48.

Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway.

Xie S, Wu H, Wang Q, Cogswell JP, Husain I, Conn C, Stambrook P, Jhanwar-Uniyal M, Dai W.

J Biol Chem. 2001 Nov 16;276(46):43305-12. Epub 2001 Sep 10.

49.

Reactive oxygen species-induced phosphorylation of p53 on serine 20 is mediated in part by polo-like kinase-3.

Xie S, Wang Q, Wu H, Cogswell J, Lu L, Jhanwar-Uniyal M, Dai W.

J Biol Chem. 2001 Sep 28;276(39):36194-9. Epub 2001 Jul 10.

50.

Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells.

Greenberg VL, Williams JM, Cogswell JP, Mendenhall M, Zimmer SG.

Thyroid. 2001 Apr;11(4):315-25.

PMID:
11349829

Supplemental Content

Loading ...
Support Center